tiprankstipranks
Advertisement
Advertisement

KAPA Stock Latest News

Expanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
RatingsExpanding Lung Cancer Franchise and Strategic Asset Acquisition Support Buy Rating on Kairos Pharma
30d ago
KAPA
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
PremiumCompany Announcements
Kairos Pharma Acquires Rights to AI-Discovered EGFR Therapy
1M ago
8K
KAPA
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
PremiumThe Fly
Kairos Pharma to acquire CL-273 from Celyn Therapeutics
1M ago
KAPA
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
PremiumThe Fly
Kairos Pharma to acquire to two clinical-stage oncology assets from Celyn
1M ago
KAPA
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
PremiumCompany Announcements
Kairos Pharma Expands Lung Cancer Pipeline With Celyn Deal
1M ago
8K
KAPA
Kairos Pharma files $75M mixed securities shelf
PremiumThe FlyKairos Pharma files $75M mixed securities shelf
3M ago
KAPA
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
Premium
Ratings
Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating
5M ago
KAPA
Kairos Pharma Approves RSUs and Cash Bonuses
Premium
Company Announcements
Kairos Pharma Approves RSUs and Cash Bonuses
6M ago
8K
KAPA
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
PremiumRatings
Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating
6M ago
KAPA
Kairos Pharma to Present at ESMO Congress 2025
PremiumCompany Announcements
Kairos Pharma to Present at ESMO Congress 2025
6M ago
8K
KAPA
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
PremiumRatings
Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma
7M ago
KAPA
Kairos Pharma Reports Positive Phase 2 Trial Results
PremiumCompany Announcements
Kairos Pharma Reports Positive Phase 2 Trial Results
7M ago
8K
KAPA
Kairos Pharma announces interim efficacy analysis of ENV105
PremiumThe FlyKairos Pharma announces interim efficacy analysis of ENV105
7M ago
KAPA
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
Premium
Ratings
Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation
7M ago
KAPA
Kairos Pharma to Host KOL Event on Phase 2 Trial
Premium
Company Announcements
Kairos Pharma to Host KOL Event on Phase 2 Trial
7M ago
8K
KAPA
Kairos Pharma Presents Phase 1 Data at Conference
PremiumCompany Announcements
Kairos Pharma Presents Phase 1 Data at Conference
7M ago
8K
KAPA
Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating
PremiumRatings
Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating
8M ago
KAPA
Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile
PremiumRatings
Optimistic Buy Rating for Kairos Pharma Driven by Promising Clinical Developments and Strong Safety Profile
8M ago
KAPA
Kairos Pharma management to meet with Maxim
PremiumThe Fly
Kairos Pharma management to meet with Maxim
8M ago
KAPA
Why Is Kairos Pharma Stock (KAPA) Up 170% Today?
PremiumMarket NewsWhy Is Kairos Pharma Stock (KAPA) Up 170% Today?
9M ago
KAPA
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
9M ago
ZK
AMD
Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook
Premium
Ratings
Promising Potential for Kairos Pharma’s ENV-105: Positive Safety Profile and Efficacy Outlook
9M ago
KAPA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >